KD Logo

Cardiff Oncology Inc [CRDF] Investment Guide: What You Need to Know

Cardiff Oncology Inc’s recent filing unveils that its Director PACE GARY W acquired Company’s shares for reported $41100.0 on Dec 19 ’23. In the deal valued at $1.37 per share,30,000 shares were bought. As a result of this transaction, PACE GARY W now holds 697,761 shares worth roughly $4.07 million.

William Blair initiated its Cardiff Oncology Inc [CRDF] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. H.C. Wainwright started covering the stock on October 22, 2020. It rated CRDF as “a Buy”.

Price Performance Review of CRDF

On Friday, Cardiff Oncology Inc [NASDAQ:CRDF] saw its stock jump 3.00% to $5.84. Over the last five days, the stock has gained 9.36%. Cardiff Oncology Inc shares have risen nearly 294.59% since the year began. Nevertheless, the stocks have risen 281.70% over the past one year. While a 52-week high of $6.42 was reached on 03/25/24, a 52-week low of $0.94 was recorded on 02/05/24. SMA at 50 days reached $3.29, while 200 days put it at $1.92. A total of 1.42 million shares were traded, compared to the trading of 0.75 million shares in the previous session.

Levels Of Support And Resistance For CRDF Stock

The 24-hour chart illustrates a support level at 5.61, which if violated will result in even more drops to 5.38. On the upside, there is a resistance level at 6.21. A further resistance level may holdings at 6.58. The Relative Strength Index (RSI) on the 14-day chart is 66.02, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.16, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 26.13%. Stochastics %K at 63.66% indicates the stock is a holding.

How much short interest is there in Cardiff Oncology Inc?

A steep rise in short interest was recorded in Cardiff Oncology Inc stocks on Mar 15, 2024, growing by 1.62 million shares to a total of 2.81 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 1.19 million shares. There was a rise of 57.65%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 6.48% of the overall stock float, the days-to-cover ratio (short ratio) rose to 0.71.

The most recent change occurred on October 08, 2020 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $25 price target.

Most Popular

[the_ad id="945"]